Conference
EP08.02-034 OCELOT - Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L
Authors
Breadner D; Liu G; Rothenstein J; Wheatley-Price P; Bains P; Cheng S; Wang Y; Sun S; Mithoowani H; Juergens R
Volume
17
Pagination
pp. s412-s413
Publisher
Elsevier
Publication Date
September 2022
DOI
10.1016/j.jtho.2022.07.716
Conference proceedings
Journal of Thoracic Oncology
Issue
9
ISSN
1556-0864